Quantcast

Obagi Medical Products’ 3-Step Acne System Provides an Effective Approach to Treating Acne Without Topical Antibiotic Exposure

July 31, 2008

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today the interim results of a 10-week study comparing CLENZIderm M.D.(TM) Acne Therapeutic Systems’ 3-step acne system for normal-to-oily skin to a leading combination benzoyl peroxide (BPO)/clindamycin antibiotic product at the American Academy of Dermatology Summer Meeting in Chicago. The data, compiled from 69 patients at week 6 of the study, show that patients with mild-to-moderately severe acne experienced comparable reductions in inflammatory and non-inflammatory lesions when using the CLENZIderm M.D. System which offers a new solubilized BPO technology.

The Obagi Medical Products 3-step acne systems, branded CLENZIderm M.D. Systems, which contain 5% solubilized BPO, help enhance the follicular penetration of BPO without the need for topical antibiotics.

“With increasing concerns regarding antibiotic resistance, there is clearly a need for improved acne therapies that do not contain antibiotics,” said Diane Thiboutot, MD, Professor and Vice Chair of Dermatology Research Co-Director, MD/PhD Program Assoc. Program Director, GCRC Penn State University College of Medicine and lead investigator of the study. “These interim results suggest that use of the CLENZIderm M.D. System may be as efficacious as a topical BPO/antibiotic combination.”

Data and Methodology

Patients were assigned facial treatment with either the 3-step acne system (CLENZIderm M.D. System for normal-to-oily skin) or the twice-daily 5% BPO/clindamycin combination product.

 NON-INFLAMMATORY LESION REDUCTION ---------------------------------------------------------------------- TREATMENT            WEEK 2           WEEK 4          WEEK 6 ---------------------------------------------------------------------- 3-step acne system   27%              40%             35% ---------------------------------------------------------------------- BPO/clindamycin      19%              30%             36% ----------------------------------------------------------------------  

 INFLAMMATORY LESION REDUCTION ---------------------------------------------------------------------- TREATMENT            WEEK 2           WEEK 4          WEEK 6 ---------------------------------------------------------------------- 3-step acne system   37%              48%             49% ---------------------------------------------------------------------- BPO/clindamycin      41%              41%             41% ---------------------------------------------------------------------- 

“Obagi Medical Products’ solubilized BPO has been studied in more than 800 patients over multiple clinical studies and continues to demonstrate compelling efficacy when compared to a leading BPO/clindamycin product,” said Steven Carlson, Chief Executive Officer of Obagi Medical Products. “Our solubilized BPO-based products have the potential to change the approach to treating acne and we are proud that Obagi Medical is at the forefront of these dermatological advancements.”

About Solubilized Benzoyl Peroxide

Obagi Medical’s proprietary, solubilized BPO, known as SoluZyl Technology, is 1/10,000 the size of any other BPO molecule available, so it can penetrate deep into the root of the follicle and treat acne where it starts. Obagi Medical’s solubilized 5% BPO is clinically proven to kill more P. acnes bacteria faster than the leading BPO/antibiotic combination product.

The solubilized BPO is available in both gel and lotion forms and can be purchased from physician offices individually or as part of a CLENZIderm M.D. Acne Therapeutic System. The System comes in two formulations, one for normal-to-oily skin patients (Gel) and one for normal-to-dry skin patients (Lotion).

About the CLENZIderm M.D. Systems

The CLENZIderm M.D. System, which uses proprietary ingredients, has two formulations based on skin type. The CLENZIderm(TM) System for normal-to-oily skin includes 2% salicylic acid cleanser and toner, and the 5% solubilized BPO gel. The CLENZIderm M.D. System for normal-to-dry skin includes a gentle cream cleanser, a therapeutic lotion containing solubilized 5% BPO and a therapeutic moisturizer with 20% glycerin and 1% dimethicone.

Of the patients who experienced signs and symptoms of treatment (erythema, peeling, dryness, burning and/or stinging) during clinical studies, the majority of cases were mild to moderate, occurred during the early weeks of treatment and decreased or resolved over time. Although rare, allergic reactions have been reported with topical benzoyl peroxide therapy.

The CLENZIderm M.D. Systems are not available over the counter and can only be obtained through physician offices.

About Obagi Medical Products, Inc. (www.obagi.com)

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical’s products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi’s skin care product introductions is as follows: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi(R) Professional-C (a line of highly stable vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R) M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm(TM) Decolletage System, January 2008. Obagi’s products are only available through physicians.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words “believes,”"expects,”"may,”"will,”"should,”"potential,”"anticipates,”"plans,” or “intends” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2007. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.




comments powered by Disqus